Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis
Status:
Completed
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2b trial
evaluating the safety and efficacy of NCX 4251 (fluticasone propionate nanocrystal)
Ophthalmic Suspension 0.1% QD for the treatment of acute exacerbations of blepharitis.